Biolexis Therapeutics
Lehi, US · Founded 2021 · Delaware corporation
Biotech
Founders & leadership
HV
Hariprasad VankayalapatiDirector
DJ
David J. BearssDirector
TH
Tyler HartmannExecutive Officer
DT
David TaylorChief Financial Officer and Secretary
JN
James N. ClarkeDirector
AS
Anthony SteveDirector
Reported raises · per SEC filings
Form D private placements▶$1.6MraisedJun 2026 · 2 investors · BiotechnologyRule 506(b)
▶$1.6MraisedJun 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tyler HartmannExecutive Officer
- Hariprasad VankayalapatiDirector
- James N. ClarkeDirector
- Anthony SteveDirector
- David J. BearssDirector
- Offering amount
- $12M
- Amount sold
- $1.6M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1MraisedOct 2023 · 1 investors · BiotechnologyRule 506(b)
▶$1MraisedOct 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Hariprasad VankayalapatiExecutive Officer, Director
- David O. TaylorExecutive Officer, Director
- Dr. David J. BearssExecutive Officer, Director
- Amount sold
- $1M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$725KraisedOct 2023 · 6 investors · BiotechnologyRule 506(b)
▶$725KraisedOct 2023 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David O. TaylorExecutive Officer, Director
- Dr. Hariprasad VankayalapatiExecutive Officer, Director
- Dr. David J. BearssExecutive Officer, Director
- Offering amount
- $725K
- Amount sold
- $725K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedSep 2022 · 2 investors · BiotechnologyRule 506(b)
▶$1.5MraisedSep 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Hariprasad VankayalapatiExecutive Officer
- Dr. David J. BearssExecutive Officer
- David O. TaylorExecutive Officer
- Amount sold
- $1.5M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$1.5MraisedMar 2022 · 17 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2022 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hariprasad VankayalapatiExecutive Officer, Director
- David TaylorExecutive Officer
- David J. BearssExecutive Officer
- Offering amount
- $2M
- Amount sold
- $1.5M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.